Neil J Korman
Overview
Explore the profile of Neil J Korman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
3466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Warren R, Pavlovsky L, Costanzo A, Bukhalo M, Korman N, Huang Y, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(2):477-481.
PMID: 39821856
No abstract available.
2.
Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb A, et al.
J Am Acad Dermatol
. 2024 Dec;
PMID: 39709077
Background: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in patients with obese. The purpose of this expert consensus panel is...
3.
Stander S, Yosipovitch G, Legat F, Reich A, Paul C, Simon D, et al.
JAMA Dermatol
. 2024 Nov;
161(2):147-156.
PMID: 39602139
Importance: Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults...
4.
Warren R, Pavlovsky L, Costanzo A, Bukhalo M, Korman N, Huang Y, et al.
Dermatol Ther (Heidelb)
. 2024 Nov;
14(12):3273-3290.
PMID: 39516454
Introduction: Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of...
5.
Korman N, Warren R, Bagel J, Armstrong A, Gooderham M, Strober B, et al.
J Dermatolog Treat
. 2024 Jun;
35(1):2371045.
PMID: 38945549
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo...
6.
Silverberg J, Eichenfield L, Hebert A, Simpson E, Gold L, Bissonnette R, et al.
J Am Acad Dermatol
. 2024 May;
91(3):457-465.
PMID: 38777187
Background: Tapinarof cream 1% once daily (QD), a topical aryl hydrocarbon receptor agonist, downregulates pro-inflammatory Th2 cytokines, upregulates skin-barrier components, and reduces oxidative stress. Objective: To assess tapinarof efficacy and...
7.
Larson E, DeMeo D, Young A, Margevicius S, Rutter J, Davies A, et al.
J Invest Dermatol
. 2024 Mar;
144(9):1963-1974.e13.
PMID: 38431222
Monocytes play a critical role in the inflammation associated with psoriasis, and their abnormalities have been reported as biomarkers of cardiovascular event risk, a psoriasis comorbidity. Monocytic cells in chronic...
8.
Burshtein J, Shah M, Zakria D, Lockshin B, Crowley J, Merola J, et al.
Dermatol Ther (Heidelb)
. 2024 Feb;
14(2):323-339.
PMID: 38340237
Introduction: Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A...
9.
Taylor S, Korman N, Tsai T, Shimomura Y, Feely M, Dutronc Y, et al.
Dermatol Ther (Heidelb)
. 2023 Sep;
13(12):3181-3191.
PMID: 37740856
Background: Baricitinib, an oral selective JAK1/JAK2 inhibitor, is approved for the treatment of adults with severe alopecia areata (AA). Objective: To evaluate differences in response up to week 52 among...
10.
Daniels P, Liou Y, Scarberry K, Sharma T, Korman N
JAAD Case Rep
. 2023 May;
35:103-107.
PMID: 37131866
No abstract available.